Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Tucatinib (Tukysa) - breast cancer

Tucatinib (Tukysa) - breast cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/50289/2021 EMEA/H/C/005263 Tukysa (tucatinib) An overview of Tukysa and why it is authorised (...) in the EU What is Tukysa and what is it used for? Tukysa is a cancer medicine that is used to treat breast cancer that is locally advanced or metastatic (has spread to other parts of the body) and when it is HER2-positive. This means the cancer cells produce a protein on their surface, HER2, which stimulates the growth of the cancer. Tukysa is used with two other medicines, capecitabine and trastuzumab, and is used after at least 2 other treatments for HER2-positive cancer have already been tried

2021 European Medicines Agency - EPARs

2. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer Full Text available with Trip Pro

Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer - PubMed This site needs JavaScript to work properly (...) generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer , , , , Affiliations Expand Affiliations 1 Division of Medical Sciences & Graduate Entry Medicine, University of Nottingham, School of Medicine, Nottingham, UK. Electronic address: john.robertson@nottingham.ac.uk. 2 Department of Oncology, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium. 3 Global Medicines Development, AstraZeneca, Cambridge

2021 EvidenceUpdates

3. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study

Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) -positive, HER2-negative metastatic breast cancer: The LEO study , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 2 Division of Hematology and Oncology, Ulsan University Hospital, Ulsan, South Korea. 3 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. 4 Center for Breast Cancer, National Cancer Center, Goyang, South Korea. 5 Center

2021 EvidenceUpdates

4. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Clinical Trial Lancet Oncol Actions . 2021 Feb;22(2):212-222. doi: 10.1016/S1470-2045(20)30642-2. Epub 2021 Jan 15. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

2021 EvidenceUpdates

5. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: xubinghe@medmail.com.cn. 2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. 3 National Cancer

2021 EvidenceUpdates

6. Breast screening: interval cancers and duty of candour toolkit

Breast screening: interval cancers and duty of candour toolkit Breast screening: interval cancers and duty of candour toolkit - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search Menu Guidance and support Take action now for new rules in 2021 Guidance (...) Breast screening: interval cancers and duty of candour toolkit Guidance on the role of breast screening and symptomatic services in identifying interval cancer and giving results to female patients. Published 11 December 2017 Last updated 24 November 2020 — From: Documents Ref: PHE Gateway number 2017648 HTML Ref: PHE Gateway number 2017648 PDF , 194KB , 1 page This file may not be suitable for users of assistive technology. Request an accessible format. If you use assistive technology

2021 Public Health England

7. A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoM) for the treatment of early and metastatic breast cancer

A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoM) for the treatment of early and metastatic breast cancer A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer - Repository of AIHTA GmbH English | Browse - - - A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer Grössmann, N. (2020 (...) ): A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer. Oncology Fact Sheet Nr. 30. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 69kB Item Type: Oncology Fact Sheet Subjects: > > > > Language: English Series Name: Oncology Fact Sheet Nr. 30 Deposited on: 09 Dec 2020 11:06 Last Modified: 09 Dec 2020 11:06 Repository Staff Only: © Copyright ,

2021 Austrian Institute of Health Technology Assessment

8. Alpelisib (Piqray) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer

Alpelisib (Piqray) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer - Repository of AIHTA GmbH English | Browse - - - Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer Grössmann, N. (2020): Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer

2021 Austrian Institute of Health Technology Assessment

9. Leuprorelin acetate (Prostap DCS) - early stage breast cancer

Leuprorelin acetate (Prostap DCS) - early stage breast cancer Published 08 February 2021 1 Product update SMC2319 leuprorelin acetate 3.75mg (Prostap® SR DCS) and 11.25mg (Prostap® 3 DCS) powder and solvent for prolonged-release suspension for injection in pre-filled syringe Takeda UK Limited 15 January 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics (...) Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission leuprorelin acetate (Prostap®) is accepted for use within NHSScotland. Indication under review: as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement). In women who have received

2021 Scottish Medicines Consortium

10. Leuprorelin acetate (Prostap DCS) - breast cancer

Leuprorelin acetate (Prostap DCS) - breast cancer Published 08 February 2021 1 Product update SMC2320 leuprorelin acetate 3.75mg (Prostap® SR DCS) and 11.25mg (Prostap® 3 DCS) powder and solvent for prolonged-release suspension for injection in pre-filled syringe Takeda UK Limited 15 January 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs (...) ) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission leuprorelin acetate (Prostap®) is accepted for use within NHSScotland. Indication under review: as treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation. Leuprorelin offers an additional treatment choice in the therapeutic class of gonadotropin- releasing hormone (GnRH) analogues for this indication. Advice context: No part of this advice may

2021 Scottish Medicines Consortium

11. Alpelisib (Piqray) - breast cancer

Alpelisib (Piqray) - breast cancer Published 08 February 2021 , Statement of advice SMC2339 alpelisib 50mg, 100mg and 200mg film-coated tablets (Piqray®) Novartis Pharmaceuticals UK Ltd 15 January 2021 ADVICE: in the absence of a submission from the holder of the marketing authorisation alpelisib (Piqray®) is not recommended for use within NHSScotland. Indication under review: in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive (...) , human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents

2021 Scottish Medicines Consortium

12. Paravertebral block for the prevention of chronic postsurgical pain after breast cancer surgery

Paravertebral block for the prevention of chronic postsurgical pain after breast cancer surgery Paravertebral block for the prevention of chronic postsurgical pain after breast cancer surgery - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. National Institutes of Health National (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Review Reg Anesth Pain Med Actions . 2021 Jan 7;rapm-2020-102040. doi: 10.1136/rapm-2020-102040. Online ahead of print. Paravertebral block for the prevention of chronic postsurgical pain after breast cancer surgery , , Affiliations Expand Affiliations 1 Anesthesia department, Hopital Ambroise-Paré

2021 EvidenceUpdates

13. Trastuzumab deruxtecan (Enhertu) - breast cancer

Trastuzumab deruxtecan (Enhertu) - breast cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/692819/2020 EMEA/H/C/005124 Enhertu (trastuzumab deruxtecan) An overview (...) of Enhertu and why it is authorised in the EU What is Enhertu and what is it used for? Enhertu is a medicine used to treat breast cancer that is metastatic (has spread to other parts of the body) or cannot be removed by surgery. It can only be used when the cancer has been shown to ‘overexpress HER2’: this means that the cancer produces a protein called HER2 in large quantities on the surface of the tumour cells, which makes the tumour cells grow more quickly. Enhertu is used on its own in patients who

2021 European Medicines Agency - EPARs

14. Tucatinib (Tukysa) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer

Tucatinib (Tukysa) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer - Repository of AIHTA GmbH English | Browse - - - Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer Grössmann, N. (2020): Tucatinib (Tukysa® (...) ) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer. Oncology Fact Sheet Nr. 37. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 74kB Item Type: Oncology Fact Sheet Subjects: > > > > Language: English Series Name: Oncology Fact Sheet Nr. 37 Deposited on: 04 Jan 2021 14:13 Last Modified: 04 Jan 2021 16:33 Repository Staff Only: © Copyright ,

2021 Austrian Institute of Health Technology Assessment

15. Trastuzumab deruxtecan (Enhertu) in patients with previously treated HER2-positive breast cancer

Trastuzumab deruxtecan (Enhertu) in patients with previously treated HER2-positive breast cancer Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer - Repository of AIHTA GmbH English | Browse - - - Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer Grössmann, N. (2020): Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer. Oncology Fact Sheet Nr. 32. Preview

2021 Austrian Institute of Health Technology Assessment

16. Pertuzumab / trastuzumab (Phesgo) - HER2-positive breast cancer

(150 out of 252 in the Phesgo group and 148 out of 248 in the pertuzumab plus trastuzumab group) had no signs of cancer in the breast and glands under the arm after one year of treatment. What are the risks associated with Phesgo? The most common side effects with Phesgo (which may affect more than 3 in 10 people) are alopecia (hair loss), diarrhoea, nausea (feeling sick), anaemia (low red blood cell counts), weakness and joint pain. The most common serious side effects with Phesgo (which may (...) Pertuzumab / trastuzumab (Phesgo) - HER2-positive breast cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/620936/2020 EMEA/H/C/005386 Phesgo (pertuzumab / trastuzumab

2021 European Medicines Agency - EPARs

17. SERM Guides: Medications to lower the risk of breast cancer

SERM Guides: Medications to lower the risk of breast cancer Resources | COSA + + + + + + > > > Resources Asia Pacific Journal of Clinical Oncology Members have free online access. Cancer Forum Read the latest issue online at: provides protocols and guidelines for Indications for Genetic Testing and the Management of Familial Cancer Syndromes. A tool to help women and their clinicians collaboratively assess and manage breast cancer risk. SERM Guides (pdf) (pdf) Position Statements Useful

2021 Clinical Oncology Society of Australia

18. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial Full Text available with Trip Pro

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial - PubMed This site needs JavaScript (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Clinical Trial Lancet Oncol Actions . 2020 Nov;21(11):1443-1454. doi: 10.1016/S1470-2045(20)30458-7. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

2021 EvidenceUpdates

19. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial

Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) navigation Clinical Trial Lancet Oncol Actions . 2020 Dec;21(12):1602-1610. doi: 10.1016/S1470-2045(20)30472-1. Epub 2020 Nov 2. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Radiation Oncology, Iridium Kankernetwerk, Wilrijk-Antwerp, Belgium; Faculty of Medicine and Health Sciences

2021 EvidenceUpdates

20. Margetuximab anti-HER2 mAb (Margenza) - To treat HER2+ breast cancer

Margetuximab anti-HER2 mAb (Margenza) - To treat HER2+ breast cancer Drug Approval Package: MARGENZA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: MARGENZA Company: MacroGenics, Inc. Application Number: 761150 Approval Date: 12/16/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2021 FDA - Drug Approval Package